6,1 1-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine | 16287-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 6,1 1-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine
• 英文别名: 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine；6,11-dihydro-5H-pyrido[3,2-c][1,5]benzodiazepine
• CAS: 16287-36-8
• 化学式: C₁₂H₁₁N₃
• 分子量: 197.239
• InChiKey: HRGUEPKMEFOQTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6,1 1-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine 在 sodium hydride 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 WAY-141608
  参考文献：
  名称：

  吡啶并二氮杂卓类：一类新型的口服活性，加压素V2受体选择性激动剂。

  摘要：

  我们寻求抗利尿肽激素精氨酸加压素（AVP）的低分子量激动剂的努力已导致临床候选药物WAY-151932（VNA-932）的鉴定。对激动剂活性的结构要求的进一步探索提供了另一类有效的，口服活性的非肽加压素V2受体选择性激动剂，例如5,11-二氢-吡啶并[2,3-b] [1,5]苯并二氮杂pine作为进一步发展的候选人。

  DOI：

  10.1016/j.bmcl.2005.10.107
• 作为产物：
  描述：

  6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-5-one hydrochloride 在 硼烷二甲硫醚络合物 作用下， 以 1,4-二氧六环 为溶剂， 以60%的产率得到6,1 1-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine
  参考文献：
  名称：

  吡啶并二氮杂卓类：一类新型的口服活性，加压素V2受体选择性激动剂。

  摘要：

  我们寻求抗利尿肽激素精氨酸加压素（AVP）的低分子量激动剂的努力已导致临床候选药物WAY-151932（VNA-932）的鉴定。对激动剂活性的结构要求的进一步探索提供了另一类有效的，口服活性的非肽加压素V2受体选择性激动剂，例如5,11-二氢-吡啶并[2,3-b] [1,5]苯并二氮杂pine作为进一步发展的候选人。

  DOI：

  10.1016/j.bmcl.2005.10.107

文献信息

• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05849735A1

  公开（公告）日：1998-12-15

  Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.

  三环化合物的一般公式I：##STR1##，如本文所述，具有V.sub.1和/或V.sub.2受体的拮抗剂活性，并在体内表现出抗利尿激素拮抗剂活性，使用这些化合物治疗以肾水过度重吸收为特征的疾病的方法，以及制备这些化合物的方法。
• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] COMPOSÉS TRICYCLIQUES INNOVANTS SERVANT D'INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089797A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，该化合物是野生型异柠檬酸脱氢酶（IDH）抑制剂：(I)。本发明还涉及将此处描述的三环化合物用于潜在治疗或预防涉及一个或多个突变IDH酶的癌症。本发明还涉及包含这些化合物的组合物。本发明还涉及将这些组合物用于潜在预防或治疗此类癌症。
• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089830A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，其为一种或多种突变IDH酶的抑制剂；其中A为-C(R1)=或-N=；X从以下组中选择：(II-i)和(II-ii)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES COMME INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089833A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), (II-ii), (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，这些化合物是一种或多种突变IDH酶的抑制剂：(I)；其中A为-C(R1)=或-N=；X选自以下组中的一种：(II-i)、(II-ii)、(II-iii)和(II-iv)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• Tricyclic vasopressin agonists
  申请人：American Home Products Corporation

  公开号：US06090803A1

  公开（公告）日：2000-07-18

  The present invention provides compounds of the general formula: ##STR1## wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

  本发明提供了一般公式如下的化合物：##STR1##其中W为O或NH，可选择性取代，以及利用这些化合物进行治疗可能通过抗利尿素激动剂活性得到缓解的紊乱的方法和药物组合物，包括尿崩症、夜尿症、夜尿、尿失禁、出血和凝血紊乱，或暂时延迟排尿。